Mayo Stephen — SEC Form 4 filings
SEC reporting owner CIK 1849061. 11 Form 4 filings on record with FilingPulse; latest filed 2026-06-23.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-03-05 to 2026-06-23. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 10,374 shares, $508,687 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 11.
- Largest priced transaction: sale of 3,135 shares @ $122.96 ($385,480) in Sarepta Therapeutics, Inc., filed 2024-03-06.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | Director | 5 | — | 2 legs · 10,374 sh · $508,687 | 5 |
| Allogene Therapeutics, Inc. (ALLO) | Director | 3 | — | — | 3 |
| Merck & Co., Inc. (MRK) | Director | 3 | — | — | 3 |
Form 4 filings — Mayo Stephen
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-23 | 4 | Allogene Therapeutics, Inc. (ALLO) | Grant/award (A): 144,400 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Sarepta Therapeutics, Inc. (SRPT) | Grant/award (A): 16,875 | EDGAR |
| 2026-06-02 | 4 | Merck & Co., Inc. (MRK) | Grant/award (A): 1,853.10 (derivative) @ $118.72 | EDGAR |
| 2026-03-13 | 4 | Sarepta Therapeutics, Inc. (SRPT) | Sale (S): 7,239 @ $17.02 | EDGAR |
| 2025-06-23 | 4 | Allogene Therapeutics, Inc. (ALLO) | Grant/award (A): 95,400 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Merck & Co., Inc. (MRK) | Grant/award (A): 2,863.09 (derivative) @ $76.84 | EDGAR |
| 2025-03-11 | 4 | Sarepta Therapeutics, Inc. (SRPT) | Grant/award (A): 2,383 · Grant/award (A): 4,792 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Allogene Therapeutics, Inc. (ALLO) | Grant/award (A): 191,082 (derivative) @ $0 | EDGAR |
| 2024-06-04 | 4 | Merck & Co., Inc. (MRK) | Grant/award (A): 1,752.43 (derivative) @ $125.54 | EDGAR |
| 2024-03-06 | 4 | Sarepta Therapeutics, Inc. (SRPT) | Sale (S): 3,135 @ $122.96 | EDGAR |
| 2024-03-05 | 4 | Sarepta Therapeutics, Inc. (SRPT) | Grant/award (A): 1,846 @ $0 · Grant/award (A): 3,679 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1849061 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →